Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy.

Nature | 2021

Alzheimer's disease (AD) is the most prevalent cause of dementia1. Although there is no effective treatment for AD, passive immunotherapy with monoclonal antibodies against amyloid beta (Aβ) is a promising therapeutic strategy2,3. Meningeal lymphatic drainage has an important role in the accumulation of Aβ in the brain4, but it is not known whether modulation of meningeal lymphatic function can influence the outcome of immunotherapy in AD. Here we show that ablation of meningeal lymphatic vessels in 5xFAD mice (a mouse model of amyloid deposition that expresses five mutations found in familial AD) worsened the outcome of mice treated with anti-Aβ passive immunotherapy by exacerbating the deposition of Aβ, microgliosis, neurovascular dysfunction, and behavioural deficits. By contrast, therapeutic delivery of vascular endothelial growth factor C improved clearance of Aβ by monoclonal antibodies. Notably, there was a substantial overlap between the gene signature of microglia from 5xFAD mice with impaired meningeal lymphatic function and the transcriptional profile of activated microglia from the brains of individuals with AD. Overall, our data demonstrate that impaired meningeal lymphatic drainage exacerbates the microglial inflammatory response in AD and that enhancement of meningeal lymphatic function combined with immunotherapies could lead to better clinical outcomes.

Pubmed ID: 33911285 RIS Download

Additional research tools detected in this publication

None found

Antibodies used in this publication

None found

Associated grants

  • Agency: NIA NIH HHS, United States
    Id: R01 AG057777
  • Agency: NIA NIH HHS, United States
    Id: R01 AG062734
  • Agency: NIH HHS, United States
    Id: AG034113
  • Agency: NIA NIH HHS, United States
    Id: UF1 AG032438
  • Agency: NIA NIH HHS, United States
    Id: RF1 AG044546
  • Agency: NINDS NIH HHS, United States
    Id: R01 NS118146
  • Agency: NIH HHS, United States
    Id: AG057496
  • Agency: NIA NIH HHS, United States
    Id: RF1 AG057496
  • Agency: NIA NIH HHS, United States
    Id: R56 AG067764
  • Agency: NIA NIH HHS, United States
    Id: P30 AG066444
  • Agency: NIA NIH HHS, United States
    Id: R37 AG034113
  • Agency: NIA NIH HHS, United States
    Id: RF1 AG053303
  • Agency: NIA NIH HHS, United States
    Id: R01 AG034113
  • Agency: NIA NIH HHS, United States
    Id: P01 AG003991
  • Agency: NIA NIH HHS, United States
    Id: P50 AG005681
  • Agency: NIA NIH HHS, United States
    Id: P01 AG026276
  • Agency: NIA NIH HHS, United States
    Id: RF1 AG058501

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Virginia University School of Medicine Genome Analysis and Technology Core Facility (service resource)

RRID:SCR_018883

Core offers instrumentation and expertise in all areas of bulk and single cell NGS genomics and transcriptomics, as well as training to access core shared instrumentations. Services include RNA Seq, CHIP Seq, ATAC Seq, Amplicon DNA Seq, 16S ribosomal gene sequencing, shot gun sequencing for small genomes and whole exome sequencing.10X Genomics resources include single cell CNV, VDJ, and 3 or 5 RNA seq as well as linked reads.Core provides real time and droplet digital PCR services most suitable for targeted gene expression, SNP genotyping and CNV discovery.

View all literature mentions